Carisoprodol (Soma) is a muscle relaxant that is metabolized into meprobamate, a schedule IV controlled substance. While carisoprodol itself is not a controlled substance in most states, its abuse potential is significant due to its sedative effects and tendency to augment other drugs like alcohol and benzodiazepines. The document reports a case study of a patient presenting with dystonic reactions due to carisoprodol withdrawal and reviews concerns about the under-recognized withdrawal syndrome. It calls for exercising appropriate caution with long-term carisoprodol prescriptions and controlling it at the federal level.